...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Hepalink IPO Document and what it says about RVX

"If eGFR was significantly increased in BETonMACE and true GFR is to be the endpoint, the size and duration of a Ph3 will be determined by the magnitude and time course of the improvement in eGFR in BETonMACE. Let’s hope those data will be presented soon." (bolding added)

What confusing me on this heading is where is the PH3 Trial coming from...specific to which trial exactly?

 

Koo

Share
New Message
Please login to post a reply